GET DAILY SIGNALSGilead Sciences (GILD) Q3 2026 Earnings Preview: Watching for a Projected -13% EPS Shift
Key Takeaways
- Gilead Sciences (GILD) reports third-quarter 2026 results on Thursday, October 29, after the market close.
- Wall Street consensus calls for adjusted earnings of roughly $2.16 per share on revenue near $7.8 billion.
- The comparison reflects an expected decline in earnings per share versus the $2.47 reported in the year-ago quarter, with revenue roughly flat.
- Investors are focused on the core HIV franchise, led by Biktarvy, and the early ramp of lenacapavir for HIV prevention.
- Management has already raised full-year 2026 base business sales guidance, signaling confidence in underlying demand.
- The prior quarter posted a headline loss tied to acquisition-related charges, even as base business sales rose 10% year over year.
Why This Earnings Report Matters
Gilead Sciences stands as a biopharmaceutical leader in HIV, liver disease, and oncology, so its quarterly update serves as an important signal for both the company and the broader specialty pharma sector. The report comes at a time when investors are assessing the staying power of the HIV franchise amid growing competitive and pricing pressures. Last quarter, Gilead beat consensus estimates on a base-business basis even while posting a headline net loss from sizable in-process research and development charges linked to acquisitions. Those charges highlight an active deal-making approach aimed at strengthening the pipeline. This time around, the focus shifts back to core operating results, new product launches, and whether the raised full-year outlook stays on course. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What Analysts Are Projecting
Analysts expect Gilead to report adjusted earnings of approximately $2.16 per share for the third quarter of 2026, a decline of roughly 13% from the $2.47 per share posted in the same period a year earlier. Consensus revenue estimates sit near $7.8 billion, essentially flat to slightly higher compared with the $7.77 billion reported in the third quarter of 2025.
The year-over-year earnings comparison is complicated by one-time items. In the second quarter of 2026, Gilead reported a loss of $6.75 per share, narrower than the roughly $7.25 loss analysts had expected, after recording about $11.2 billion in IPR&D charges tied to its acquisitions of Arcellx, Tubulis, and Ouro. On an operating basis, base business sales grew 10% year over year to $7.6 billion, with HIV sales up 12% to $5.7 billion. Management subsequently raised its full-year base business sales outlook to a range of $29.8 billion to $30.1 billion, representing growth of 6% to 7%.
Key metrics to watch include Biktarvy sales, the uptake of lenacapavir (marketed for HIV prevention as Yeztugo), oncology growth from Trodelvy, and any updates to full-year guidance.
Market Sentiment Heading Into the Report
Sentiment heading into the report leans cautiously optimistic. Gilead shares have climbed notably since the company's last earnings release, and the stock carries a consensus "Moderate Buy" rating with an average price target near $160. The company has beaten consensus earnings estimates in each of its last four quarters, which has helped support confidence despite headline volatility from acquisition charges.
Still, risks remain. The expected year-over-year decline in earnings per share reflects a tough comparison, and investors will be sensitive to any softness in the core HIV franchise or signs that new product launches are ramping more slowly than hoped. Competitive dynamics in HIV prevention and oncology, along with the impact of pricing changes such as Medicare Part D redesign, are also factors that could shape the immediate post-earnings reaction.
Guidance, Pipeline, and What Comes Next
Following the report, investors will look to management's commentary on the full-year 2026 outlook. Gilead has already guided base business sales to a range of $29.8 billion to $30.1 billion and HIV sales growth of 9% to 10%, so confirmation or adjustment of those targets will be a central focus.
The HIV franchise remains the company's growth engine. Sustained momentum in Biktarvy and the continued rollout of lenacapavir for pre-exposure prophylaxis (PrEP), a preventive HIV treatment, will be closely watched. Yeztugo has already surpassed a $1 billion annualized run rate, and investors will want to see that trajectory continue.
On the pipeline front, upcoming regulatory catalysts matter. The company has pointed to a U.S. Food and Drug Administration (FDA) decision on the combination treatment bictegravir plus lenacapavir and, separately, a decision on the anito-cel cell therapy candidate from Arcellx expected in December. Oncology performance, led by Trodelvy, provides another signal of diversification.
Cost management will also be important. The large IPR&D charges from recent acquisitions have pressured reported earnings, so investors will be watching whether research and development and selling expenses remain controlled as the company integrates new programs. Balance across growth, pipeline execution, and cost discipline is likely to define the investment narrative into 2027.
Integrating AI Tools Into Earnings Analysis
In my own research, I have found Tickeron’s AI Screener to be a useful complement when preparing for reports like this one. It allows quick filtering across thousands of stocks using technical patterns, fundamentals, and AI signals, which helps put Gilead’s metrics in broader context without replacing traditional earnings analysis. The tool’s customizable options for industry, market cap, and performance make it straightforward to identify comparable names and spot potential trade ideas around upcoming catalysts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
GILD's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for GILD turned positive on October 14, 2026. Looking at past instances where GILD's MACD turned positive, the stock continued to rise in 38 of 55 cases over the following month. The odds of a continued upward trend are 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on GILD as a result. In 52 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
Following a +6.39% 3-day Advance, the price is estimated to grow further. Considering data from situations where GILD advanced for three days, in 216 of 336 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 136 of 271 cases where GILD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 50%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 29 of 61 cases where GILD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 48%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GILD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
GILD broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 10 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 17 (best 1 - 100 worst), indicating outstanding price growth. GILD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.099) is normal, around the industry mean (-3.196). GILD's P/E Ratio (-58.839) is considerably lower than the industry average of (21.213). Projected Growth (PEG Ratio) (2.263) is also within normal values, averaging (5.738). Dividend Yield (0.021) settles around the average of (0.041) among similar stocks. P/S Ratio (6.053) is also within normal values, averaging (4.033).
The Tickeron Seasonality Score of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutic products and treatments for life threatening diseases
Industry PharmaceuticalsMajor
Advertisement